Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model

• Published in: Scientific reports Vol. 6; no. 1; p. 35233
• Main Authors: Ke, Ke, Li, Qi, Yang, Xiaofeng, Xie, Zhijian, Wang, Yu, Shi, Jue, Chi, Linfeng, Xu, Weijian, Hu, Lingling, Shi, Huali
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.10.2016; Nature Publishing Group
• Subjects: 1-Phosphatidylinositol 3-kinase; 13/21; 14/63; 38/1; 38/39; 38/77; 631/154/436/2388; 692/699/2743/316/801; 82/1; 82/80; AKT protein; Animals; Bone marrow; Bone Marrow - drug effects; Calcification; Cbfa-1 protein; Cell Differentiation - drug effects; Cell proliferation; Cholecystokinin; Disease Models, Animal; Drugs, Chinese Herbal - administration & dosage; Drugs, Chinese Herbal - chemistry; Gene Expression Regulation, Developmental - drug effects; Herbal medicine; Humanities and Social Sciences; Humans; multidisciplinary; Oncogene Protein v-akt - genetics; Osteoblasts; Osteogenesis - drug effects; Osteogenesis - genetics; Osteoporosis; Osteoporosis - drug therapy; Osteoporosis - genetics; Osteoporosis - pathology; Ovariectomy; Phosphatidylinositol 3-Kinases - genetics; Ranunculaceae - chemistry; Rats; Rodents; Saponins - administration & dosage; Saponins - chemistry; Science; Signal transduction; Signal Transduction - drug effects; Signal Transduction - genetics; Stromal cells; Stromal Cells - drug effects; Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep35233

Asperosaponin VI (ASA VI), a natural compound isolated from the well-known traditional Chinese herb Radix Dipsaci , has an important role in promoting osteoblast formation. However, its effects on osteoblasts in the context of osteoporosis is unknown. This study aimed to investigate the effects and mechanism of ASA VI action on the proliferation and osteogenic differentiation of bone marrow stromal cells isolated from the ovariectomized rats (OVX rBMSCs). The toxicity of ASA VI and its effects on the proliferation of OVX rBMSCs were measured using a CCK-8 assay. Various osteogenic differentiation markers were also analyzed, such as ALP activity, calcified nodule formation, and the expression of osteogenic genes, i.e., ALP, OCN, COL 1 and RUNX2. The results indicated that ASA VI promoted the proliferation of OVX rBMSCs and enhanced ALP activity and calcified nodule formation. In addition, while ASA VI enhanced the expression of ALP, OCN, Col 1 and RUNX2, treatment with LY294002 reduced all of these osteogenic effects and reduced the p-AKT levels induced by ASA VI. These results suggest that ASA VI promotes the osteogenic differentiation of OVX rBMSCs by acting on the phosphatidylinositol—3 kinase/AKT signaling pathway.